Do patients with atrial fibrillation need to take anticoagulants long-term?

Not all patients with atrial fibrillation (AF) require long-term anticoagulant therapy; the decision to initiate anticoagulation depends on an individual’s thrombotic risk level. Patients at low risk do not require anticoagulation, whereas those at intermediate or high risk need long-term, standardized anticoagulant treatment to reduce the risk of thrombus formation and ischemic stroke. Prompt medical evaluation is essential if symptoms such as limb numbness or speech disturbances occur.

Atrial fibrillation disrupts the heart’s normal rhythm, slowing blood flow in the atria and predisposing to blood stasis and thrombus formation. If a thrombus dislodges, it may travel via the bloodstream and occlude cerebral or peripheral arteries, leading to severe vascular complications. Clinically, thrombotic risk is assessed based on age, comorbidities, and organ function, and patients are stratified into risk categories to guide appropriate anticoagulation strategies.

For low-risk AF patients, management focuses primarily on rhythm control and regular clinical monitoring, without anticoagulant intervention. In contrast, intermediate- and high-risk patients should adhere consistently to oral anticoagulants, which inhibit platelet aggregation and thrombus formation. For patients who cannot tolerate anticoagulant medications, left atrial appendage occlusion (LAAO) surgery offers an alternative: by sealing off the primary site of thrombus formation, it provides effective stroke prevention without pharmacotherapy.

Maintaining emotional stability and consistent daily routines, limiting intake of high-fat and high-salt foods, engaging in moderate physical activity to stabilize heart rate, and regularly monitoring both cardiac rhythm and coagulation parameters—all contribute to preserving overall cardiovascular homeostasis.